<DOC>
	<DOC>NCT02830789</DOC>
	<brief_summary>This study investigates whether calcium citrate or calcium carbonate are the optimal supplement to treat secondary hyperparathyroidism following Roux-en-Y gastric bypass operation. Half of the participants will be randomized to receive calcium citrate, while the other half will receive calcium carbonate. The study will be double blinded.</brief_summary>
	<brief_title>Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>RouxenY gastric bypass operation â‰¥12 months ago Parathyroid hormone &gt; 6.9 pmol/l Vitamin D &gt; 50 nmol/l PCalcium [1.181.32] mmol/l Liver disease Renal disease Hypercalcemia Untreated thyroid disease Parathyroid disease except secondary hyperparathyroidism Use of diuretics, bisphosphonates, calcitonin, teriparatide, oral corticosteroids, anabolic steroids, calcimimetics, lithium, strontium, denosumab or anticonvulsants within 1 year of inclusion abusing alcohol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>